Xenitra Secures Exclusive $5M Biomiq Skincare Deal in Greater China
Xenitra Limited has locked in a four-year exclusive distribution agreement for Biomiq Skincare in Greater China, targeting $5 million in minimum purchases and integrating the brand into its blockchain tokenised sales ecosystem.
- Four-year exclusive distribution deal with $5 million minimum purchase target
- Biomiq Skincare specialises in acne, minor skin conditions, and anti-aging
- Integration into Xenitra's OPAL blockchain tokenised sales platform
- Launch scheduled for August 2026 across Greater China
- Related party director disclosed and abstained from approval
Exclusive Distribution Deal Targets $5 Million in Sales
Xenitra Limited (ASX:XEN) has secured exclusive distribution rights for the Australian-made Biomiq Skincare brand across Greater China under a four-year agreement with Servatus Ltd. The deal includes a minimum purchase commitment escalating from $0.5 million in the first year to $2 million in the fourth, totalling $5 million to maintain exclusivity.
Biomiq Skincare, developed by Australian Biotherapeutics in Queensland, offers over 20 products focusing on acne treatment, minor skin conditions like eczema and psoriasis, and a potent anti-aging range tailored for menopause and perimenopause skin care. The brand has rapidly grown in Australia since its 2022 launch, driven by social media and online marketing.
Integration with Blockchain Tokenised Sales Ecosystem
This agreement marks Biomiq as the second major brand to join Xenitra’s OPAL blockchain tokenised sales ecosystem, following the April launch of EZZ Life Sciences products. The OPAL platform aims to create a self-reinforcing commercial flywheel, enhancing consumer engagement and loyalty through product authentication, traceability, and a loyalty rewards program.
Xenitra’s Non-Executive Chairman, Dr Anthony Noble, highlighted the skincare range’s fit with the tokenised sales channel, noting early sales approaching $1 million within six weeks. He emphasised the ecosystem’s capacity to deepen customer engagement and support premium international brands entering Asian markets.
Governance and Contractual Details
The distribution agreement, effective from 2 June 2026 with a planned product launch in August, includes automatic three-year renewal terms beyond the initial four years unless terminated with notice. Payment terms require 50% upfront on invoicing and the remainder within 75 days.
Dr Noble is also an Executive Director of Servatus but holds no shares in either company and abstained from voting on the agreement’s approval to manage potential conflicts. Independent directors approved the deal on arm’s length terms, including Servatus’s capacity to meet supply commitments.
Xenitra’s move follows its recent expansion of blockchain-enabled FMCG sales in China, where its OPAL ecosystem surpassed $500,000 in sales within the first month, onboarding over 130 distributors. The Biomiq deal could significantly scale this momentum by adding a fast-growing skincare brand with strong consumer appeal.
Bottom Line?
Xenitra’s exclusive Biomiq deal deepens its foothold in China’s lucrative skincare market while advancing its blockchain sales model, but meeting escalating purchase targets will be key to sustaining exclusivity.
Questions in the middle?
- Will Biomiq’s Australian success translate to sustained growth in China’s competitive skincare market?
- How effectively can Xenitra’s OPAL tokenised ecosystem drive consumer loyalty and repeat purchases for Biomiq?
- What regulatory or market risks could impact blockchain-enabled sales channels in Greater China?
